Brand Name
Simlandi
Generic Name
Adalimumab-ryvk
View Brand Information FDA approval date: May 20, 2024
Form: Kit
What is Simlandi (Adalimumab-ryvk)?
SIMLANDI is a tumor necrosis factor blocker indicated for: Rheumatoid Arthritis : Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment